Skip to Main content Skip to Navigation
Journal articles

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib

Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03623680
Contributor : François Bertucci Connect in order to contact the contributor
Submitted on : Tuesday, March 29, 2022 - 6:29:06 PM
Last modification on : Wednesday, May 25, 2022 - 3:40:02 PM

Identifiers

Citation

Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray-Coquard, Axel Le Cesne, et al.. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. European Journal of Cancer, Elsevier, 2020, 126, pp.45-55. ⟨10.1016/j.ejca.2019.12.001⟩. ⟨hal-03623680⟩

Share

Metrics

Record views

9